Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer


Mariana Watanabe Garcia

University of São Paulo , Brazil

Title: Adjuvant potential of outer membrane vesicles from Neisseria lactamica


Biography: Mariana Watanabe Garcia


Outer membrane vesicles or OMVs are derived from evaginations of Gram-negative bacteria outer membrane and they have gained immunological interest especially in relation to their ability to modulate biological functions and to be an alternative to the development of new vaccine strategies and combinations thereof. OMVs from commensal bacterium Neisseria lactamica induce antibodies which have cross reactivity with N. meningitidis and may be both antigen to meningococcal disease and a potential mucosal adjuvant. The objective of this study was to evaluate the adjuvant function of Neisseria lactamica OMVs using the surface protein PspA5 from Streptococcus pneumoniae as antigen model. OMVs were obtained from cultivations of the bacteria in bench scale bioreactor. The immunoassays were performed with OMVs in natura formulation (pure) and OMVs purified with sodium deoxycholate (DOC) at 0.3% and 0.5% in order to remove part of its lipopolysaccharide (LOS). The immunization groups were divided into 5 control groups: (1) Non, (2) PspA5, (3) pure OMV (OMVpure), (4) OMV purified with DOC 0.3% (OMV0.3%), (5) OMV purified with DOC 0.5% (OMV0.5%) and 3 vaccinated groups: (6) PspA5 in combination with OMVpure, (7) PspA5 in combination with OMV0,3% and (8) PspA5 in combination with OMV0.5%. The schedule set 2 intranasal fortnightly doses in murine model. It was evaluated the induction of anti-PspA5 IgG antibodies (IgG, IgG1 and IgG2a) and the protective potential of the different formulation. Initial immunological tests showed determinant adjuvant activity of all OMVs using the heterologous protein PspA5 as antigen model and protection against survival challenge.